EMA accepts marketing authorisation applications for Idefirix and Xospata
European regulators have accepted for review marketing authorisation applications for Hansa’s Idefirix and Astellas’ Xospata.
Read More
Tag: Astella
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
